Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Illinois Tech Journal.
Press releases published on August 25, 2025
Global Suppositories Market to Surpass USD 2.05 Billion by 2030 | MarketsandMarkets™
GlobeNewswire
·
August 25, 2025
Delray Beach, FL, Aug. 25, 2025 (GLOBE NEWSWIRE) -- The global suppositories market, valued at US$1.56 billion in 2024, stood at US$1.63 billion in 2025 and is projected to advance at a resilient CAGR of 4.7% from 2025 to 2030, culminating in a forecasted …
VERSES® Receives Patent for Specifying Domain Models with Active Inference Agents
GlobeNewswire
·
August 25, 2025
VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSF) (“VERSES” or the “Company”), a cognitive computing company specializing in next-generation agentic software systems, today announces that a patent was …
AITX’s RAD Launches Logistics Market Solution With ROAMEO
GlobeNewswire
·
August 25, 2025
Client Feedback from Complete RAD Security Solution Offers Significant Potential Detroit, Michigan, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Artificial Intelligence Technology Solutions, Inc. (the “Company”) (OTCID:AITX), along with its wholly owned subsidiary, …
Global Veterinary Diagnostics Market Set to Reach USD 5.36 Billion by 2030 | MarketsandMarkets™
GlobeNewswire
·
August 25, 2025
Delray Beach, FL, Aug. 25, 2025 (GLOBE NEWSWIRE) -- The global veterinary diagnostics market, valued at US$3.42 billion in 2024, stood at US$3.68 billion in 2025 and is projected to advance at a resilient CAGR of 7.8% from 2025 to 2030, culminating in a …
PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer
GlobeNewswire
·
August 25, 2025
Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months* VERSATILE-003 Phase 3 trial in progress PRINCETON, N.J., Aug. 25, 2025 (GLOBE …
Biofrontera Inc. Announces Last-Patient-Out in Phase 2b Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% for the Treatment of Moderate to Severe Acne Vulgaris
GlobeNewswire
·
August 25, 2025
Final patient visit marks key milestone for Biofrontera, with top-line results expected Q1 2026 Company plans FDA discussion in Q3 2026 to advance Phase 3 program and potential label expansion More than 50 million people affected by acne in US each year, …
24/7 Market News: LIXTE Targets Large, Unmet Oncology Markets
GlobeNewswire
·
August 25, 2025
DENVER, Aug. 25, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com, a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, revisits LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage …
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
GlobeNewswire
·
August 25, 2025
CORAL GABLES, Fla., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for …
HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market
GlobeNewswire
·
August 25, 2025
Company’s pembrolizumab-based immune checkpoint inhibitor exhibited success against solid tumors in IND-enabling studies by simultaneously activating immune cells and promoting their infiltration into solid tumors Presentation at Nova Southeastern …
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025
GlobeNewswire
·
August 25, 2025
DUBLIN and BRIDGEWATER, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced upcoming presentations at the European Society of Cardiology (ESC) Congress 2025, August 29th-September 1st, in Madrid, Spain, where new …
Arnatar Therapeutics Emerges from Stealth and Announces Receipt of FDA Orphan Drug and Rare Pediatric Disease Designations for ART4
GlobeNewswire
·
August 25, 2025
SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Arnatar Therapeutics, a biotechnology company pioneering RNA-based therapies for severe and underserved diseases, emerges from stealth today and announces that the U.S. Food and Drug Administration (FDA) has …
Smarter, Faster, and More Human: Cerence AI and Volkswagen Advance Partnership to Deliver Next-Gen In-Car Conversations
GlobeNewswire
·
August 25, 2025
BURLINGTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cerence Inc. (NASDAQ: CRNC) (“Cerence AI”), a global leader pioneering conversational AI-powered user experiences, today announced the next evolution of its successful collaboration with the Volkswagen …
SCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025
GlobeNewswire
·
August 25, 2025
JERSEY CITY, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that the Scynexis senior …
Cassava Sciences to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire
·
August 25, 2025
AUSTIN, Texas, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, such as Tuberous …
Collegium to Present Nine Real-World Data Posters at PAINWeek 2025 Annual Meeting
GlobeNewswire
·
August 25, 2025
STOUGHTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present nine posters showcasing real-world data from its differentiated pain portfolio at PAINWeek 2025, taking place in Las Vegas, NV …
Avalyn to Participate in Multiple Upcoming Investor Conferences in September
GlobeNewswire
·
August 25, 2025
CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced that management …
Locafy to Present at the 2025 Gateway Conference on September 3rd
GlobeNewswire
·
August 25, 2025
PERTH, Australia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Locafy Limited (Nasdaq: LCFY, LCFYW) (“Locafy” or the “Company”), a globally recognized software-as-a-service technology company specializing in ”entity-based” search engine optimization (SEO), will …
NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September
GlobeNewswire
·
August 25, 2025
NAARDEN, The Netherlands and MIAMI, Aug. 25, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at …
Ardelyx to Participate in Upcoming Investor Conferences
GlobeNewswire
·
August 25, 2025
WALTHAM, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today …
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in September 2025
GlobeNewswire
·
August 25, 2025
ROCKVILLE, Md. and SUZHOU, China, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) (“Ascentage Pharma” or the “Company”), a global, commercial stage, integrated biopharmaceutical company engaged in the …